| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Rossi Christina | Chief Operating Officer | C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE | /s/ Melissa Masse, Attorney-in-Fact | 2025-07-21 | 0001756941 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BPMC | Common Stock | Award | +39.5K | +62.09% | 103K | Jul 17, 2025 | Direct | F1, F2, F3 | ||
| transaction | BPMC | Common Stock | Disposed to Issuer | -82.4K | -79.97% | 20.6K | Jul 17, 2025 | Direct | F1, F2, F3, F4 | ||
| transaction | BPMC | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -20.6K | -100% | 0 | Jul 17, 2025 | Direct | F1, F2, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BPMC | Stock Option (Right to Buy) | Disposed to Issuer | -80K | -100% | 0 | Jul 17, 2025 | Common Stock | 80K | $65.75 | Direct | F1, F2, F6 | ||
| transaction | BPMC | Stock Option (Right to Buy) | Disposed to Issuer | -6.5K | -100% | 0 | Jul 17, 2025 | Common Stock | 6.5K | $86.60 | Direct | F1, F2, F6 | ||
| transaction | BPMC | Stock Option (Right to Buy) | Disposed to Issuer | -28.5K | -100% | 0 | Jul 17, 2025 | Common Stock | 28.5K | $54.13 | Direct | F1, F2, F6 | ||
| transaction | BPMC | Stock Option (Right to Buy) | Disposed to Issuer | -26.1K | -100% | 0 | Jul 17, 2025 | Common Stock | 26.1K | $100.13 | Direct | F1, F2, F6 | ||
| transaction | BPMC | Stock Option (Right to Buy) | Disposed to Issuer | -30K | -100% | 0 | Jul 17, 2025 | Common Stock | 30K | $61.31 | Direct | F1, F2, F6 | ||
| transaction | BPMC | Stock Option (Right to Buy) | Disposed to Issuer | -30K | -100% | 0 | Jul 17, 2025 | Common Stock | 30K | $43.15 | Direct | F1, F2, F6 | ||
| transaction | BPMC | Stock Option (Right to Buy) | Disposed to Issuer | -30K | -100% | 0 | Jul 17, 2025 | Common Stock | 30K | $95.12 | Direct | F1, F2, F6 | ||
| transaction | BPMC | Stock Option (Right to Buy) | Disposed to Issuer | -26.4K | -100% | 0 | Jul 17, 2025 | Common Stock | 26.4K | $96.57 | Direct | F1, F2, F6 |
Christina Rossi is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). |
| F2 | Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. |
| F3 | Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award. |
| F4 | Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award. |
| F5 | Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration. |
| F6 | Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |